Circulating levels of endocannabinoids and oxylipins altered by dietary lipids in older women are likely associated with previously identified gene targets

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1861, Issue 11, 2016, Pages 1693-1704

  Watkins, Bruce A ^a,b   Kim, Jeffrey ^a   Kenny, Anne ^b   Pedersen, Theresa L ^c   Pappan, Kirk L ^d   Newman, John W ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c AGRICULTURAL RESEARCH SERVICE   (United States)

^d METABOLON INC   (United States)

Author keywords

Endocannabinoids; Global metabolites; Oxylipins; Postmenopausal women

Indexed keywords

AMINO ACID; ARACHIDONIC ACID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DOCOSAHEXAENOIC ACID; ENDOCANNABINOID; EPOXIDE; FATTY ACID; FISH OIL; GLUCOSE TRANSPORTER 1; GLYCEROLIPID; ICOSAPENTAENOIC ACID; LYSOGLYCEROLIPID; N 6 ACYLETHANOLAMIDE; OLEIC ACID; OMEGA 3 FATTY ACID; OXYLIPIN; PLACEBO; STEROID HORMONE; STEROL; UNCLASSIFIED DRUG; FAT INTAKE; GLYCEROPHOSPHOLIPID;

AGED; AGING; ARTICLE; CELL CULTURE; DIETARY SUPPLEMENT; FAT INTAKE; FATTY ACID BLOOD LEVEL; FEMALE; GENE IDENTIFICATION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; INSULIN RESISTANCE; LIPID COMPOSITION; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; METABOLOMICS; MYOBLAST; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ADMINISTRATION AND DOSAGE; BLOOD; CLUSTER ANALYSIS; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LEAST SQUARE ANALYSIS; METABOLISM; METABOLOME; PHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL;

AGED; AMINO ACIDS; CLUSTER ANALYSIS; DIETARY FATS; DIETARY SUPPLEMENTS; DISCRIMINANT ANALYSIS; ENDOCANNABINOIDS; FATTY ACIDS; FATTY ACIDS, OMEGA-3; FEMALE; GENE EXPRESSION REGULATION; GLYCEROPHOSPHOLIPIDS; HUMANS; LEAST-SQUARES ANALYSIS; METABOLOME; METABOLOMICS; OXYLIPINS; POSTMENOPAUSE;

EID: 84982275278     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2016.07.007     Document Type: Article

References (57)

1. [1] Harris, W.S., Pottala, J.V., Varvel, S.A., Borowski, J.J., Ward, J.N., McConnell, J.P., Erythrocyte omega-3 fatty acids increase and linoleic acid decreases with age: observations from 160,000 patients. Prostaglandins Leukot. Essent. Fat. Acids 88 (2013), 257–263.
2. [2] Stark, K.D., Mulvad, G., Pedersen, H.S., Park, E.J., Dewailly, E., Holub, B.J., Fatty acid compositions of serum phospholipids of postmenopausal women: a comparison between Greenland Inuit and Canadians before and after supplementation with fish oil. Nutrition 18 (2002), 627–630.
3. [3] Tartibian, B., Hajizadeh Maleki, B., Kanaley, J., Sadeghi, K., Long-term aerobic exercise and omega-3 supplementation modulate osteoporosis through inflammatory mechanisms in post-menopausal women: a randomized, repeated measures study. Nutr. Metab. (Lond.), 8, 2011, 71.
4. [4] Hu, F.B., Bronner, L., Willett, W.C., Stampfer, M.J., Rexrode, K.M., Albert, C.M., Hunter, D., Manson, J.E., Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 287 (2002), 1815–1821.
5. [5] Davidson, M.H., Stein, E.A., Bays, H.E., Maki, K.C., Doyle, R.T., Shalwitz, R.A., Ballantyne, C.M., Ginsberg, H.N., Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin. Ther 29 (2007), 1354–1367.
6. [6] Hu, F.B., Cho, E., Rexrode, K.M., Albert, C.M., Manson, J.E., Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation 107 (2003), 1852–1857.
7. [7] Erkkila, A.T., Lichtenstein, A.H., Mozaffarian, D., Herrington, D.M., Fish intake is associated with a reduced progression of coronary artery atherosclerosis in postmenopausal women with coronary artery disease. Am. J. Clin. Nutr 80 (2004), 626–632.
8. [8] Kim, J., Li, Y., Watkins, B.A., Fat to treat fat: emerging relationship between dietary PUFA, endocannabinoids, and obesity. Prostaglandins Other Lipid Mediat 104-105 (2013), 32–41.
9. [9] Eckardt, K., Sell, H., Taube, A., Koenen, M., Platzbecker, B., Cramer, A., Horrighs, A., Lehtonen, M., Tennagels, N., Eckel, J., Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia 52 (2009), 664–674.
10. [10] Ofek, O., Karsak, M., Leclerc, N., Fogel, M., Frenkel, B., Wright, K., Tam, J., Attar-Namdar, M., Kram, V., Shohami, E., Mechoulam, R., Zimmer, A., Bab, I., Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 696–701.
11. [11] Hu, S.S., Bradshaw, H.B., Chen, J.S., Tan, B., Walker, J.M., Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity. Br. J. Pharmacol 153 (2008), 1538–1549.
12. [12] Kim, J., Carlson, M.E., Watkins, B.A., Docosahexaenoyl ethanolamide improves glucose uptake and alters endocannabinoid system gene expression in proliferating and differentiating C2C12 myoblasts. Front. Physiol, 5, 2014, 100.
13. [13] Kim, J., Carlson, M.E., Kuchel, G.A., Newman, J.W., Watkins, B.A., Dietary DHA reduces downstream endocannabinoid and inflammatory gene expression and epididymal fat mass while improving aspects of glucose use in muscle in C57BL/6J mice. Int. J. Obes, 2015.
14. [14] Lundstrom, S.L., Yang, J., Brannan, J.D., Haeggstrom, J.Z., Hammock, B.D., Nair, P., O'Byrne, P., Dahlen, S.E., Wheelock, C.E., Lipid mediator serum profiles in asthmatics significantly shift following dietary supplementation with omega-3 fatty acids. Mol. Nutr. Food Res 57 (2013), 1378–1389.
15. [15] Howe, G.A., Schilmiller, A.L., Oxylipin metabolism in response to stress. Curr. Opin. Plant Biol 5 (2002), 230–236.
16. [16] Spector, A.A., Fang, X., Snyder, G.D., Weintraub, N.L., Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog. Lipid Res 43 (2004), 55–90.
17. [17] Watkins, B.A., Lippman, H.E., Le Bouteiller, L., Li, Y., Seifert, M.F., Bioactive fatty acids: role in bone biology and bone cell function. Prog. Lipid Res 40 (2001), 125–148.
18. [18] Gravaghi, C., La Perle, K.M., Ogrodwski, P., Kang, J.X., Quimby, F., Lipkin, M., Lamprecht, S.A., Cox-2 expression, PGE(2) and cytokines production are inhibited by endogenously synthesized n − 3 PUFAs in inflamed colon of fat-1 mice. J. Nutr. Biochem 22 (2011), 360–365.
19. [19] Li, Y., Seifert, M.F., Lim, S.Y., Salem, N. Jr., Watkins, B.A., Bone mineral content is positively correlated to n − 3 fatty acids in the femur of growing rats. Br. J. Nutr. 104 (2010), 674–685.
20. [20] Grapov, D., Adams, S.H., Pedersen, T.L., Garvey, W.T., Newman, J.W., Type 2 diabetes associated changes in the plasma non-esterified fatty acids, oxylipins and endocannabinoids. PLoS One, 7, 2012, e48852.
21. [21] Psychogios, N., Hau, D.D., Peng, J., Guo, A.C., Mandal, R., Bouatra, S., Sinelnikov, I., Krishnamurthy, R., Eisner, R., Gautam, B., Young, N., Xia, J., Knox, C., Dong, E., Huang, P., Hollander, Z., Pedersen, T.L., Smith, S.R., Bamforth, F., Greiner, R., McManus, B., Newman, J.W., Goodfriend, T., Wishart, D.S., The human serum metabolome. PLoS One, 6, 2011, e16957.
22. [22] Evans, A.M., DeHaven, C.D., Barrett, T., Mitchell, M., Milgram, E., Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal. Chem 81 (2009), 6656–6667.
23. [23] Ohta, T., Masutomi, N., Tsutsui, N., Sakairi, T., Mitchell, M., Milburn, M.V., Ryals, J.A., Beebe, K.D., Guo, L., Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol. Pathol 37 (2009), 521–535.
24. [24] Boudonck, K.J., Mitchell, M.W., Nemet, L., Keresztes, L., Nyska, A., Shinar, D., Rosenstock, M., Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol. Pathol 37 (2009), 280–292.
25. [25] Dehaven, C.D., Evans, A.M., Dai, H., Lawton, K.A., Organization of GC/MS and LC/MS metabolomics data into chemical libraries. J. Cheminform., 2, 2010, 9.
26. [26] Storey, J.D., Tibshirani, R., Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 9440–9445.
27. [27] R Development Core Team, R: A Language and Environment for Statistical Computing., R Foundation for Statistical Computing. Retrieved from http://www.R-project.org (Vienna, Austria), 2013.
28. [28] Grapov, D., Newman, J.W., imDEV: a graphical user interface to R multivariate analysis tools in Microsoft Excel. Bioinformatics 28 (2012), 2288–2290.
29. [29] Wehrens, R., Chemometrics with R: Multivariate Data Analysis in the Natural Sciences and Life Sciences, Use R. 2011, 1–281.
30. [30] Mevik, B.H., Wehrens, R., The pls package: principal component and partial least squares regression in R. J. Stat. Softw 18 (2007), 1–23.
31. [31] Keenan, A.H., Pedersen, T.L., Fillaus, K., Larson, M.K., Shearer, G.C., Newman, J.W., Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers. J. Lipid Res 53 (2012), 1662–1669.
32. [32] Nording, M.L., Yang, J., Georgi, K., Hegedus Karbowski, C., German, J.B., Weiss, R.H., Hogg, R.J., Trygg, J., Hammock, B.D., Zivkovic, A.M., Individual variation in lipidomic profiles of healthy subjects in response to omega-3 fatty acids. PLoS One, 8, 2013, e76575.
33. [33] Shearer, G.C., Harris, W.S., Pedersen, T.L., Newman, J.W., Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. J. Lipid Res 51 (2010), 2074–2081.
34. [34] Prentki, M., Madiraju, S.R., Glycerolipid metabolism and signaling in health and disease. Endocr. Rev. 29 (2008), 647–676.
35. [35] Berger, A., Crozier, G., Bisogno, T., Cavaliere, P., Innis, S., Di Marzo, V., Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 6402–6406.
36. [36] Yang, R., Fredman, G., Krishnamoorthy, S., Agrawal, N., Irimia, D., Piomelli, D., Serhan, C.N., Decoding functional metabolomics with docosahexaenoyl ethanolamide (DHEA) identifies novel bioactive signals. J. Biol. Chem 286 (2011), 31532–31541.
37. [37] Vuong, L.A., Mitchell, V.A., Vaughan, C.W., Actions of N-arachidonyl-glycine in a rat neuropathic pain model. Neuropharmacology 54 (2008), 189–193.
38. [38] Huang, S.M., Bisogno, T., Petros, T.J., Chang, S.Y., Zavitsanos, P.A., Zipkin, R.E., Sivakumar, R., Coop, A., Maeda, D.Y., De Petrocellis, L., Burstein, S., Di Marzo, V., Walker, J.M., Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J. Biol. Chem 276 (2001), 42639–42644.
39. [39] Matias, I., Gonthier, M.P., Orlando, P., Martiadis, V., De Petrocellis, L., Cervino, C., Petrosino, S., Hoareau, L., Festy, F., Pasquali, R., Roche, R., Maj, M., Pagotto, U., Monteleone, P., Di Marzo, V., Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab 91 (2006), 3171–3180.
40. [40] Matias, I., Carta, G., Murru, E., Petrosino, S., Banni, S., Di Marzo, V., Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. Biochim. Biophys. Acta 1781 (2008), 52–60.
41. [41] Di Marzo, V., Verrijken, A., Hakkarainen, A., Petrosino, S., Mertens, I., Lundbom, N., Piscitelli, F., Westerbacka, J., Soro-Paavonen, A., Matias, I., Van Gaal, L., Taskinen, M.R., Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur. J. Endocrinol 161 (2009), 715–722.
42. [42] Engeli, S., Bohnke, J., Feldpausch, M., Gorzelniak, K., Janke, J., Batkai, S., Pacher, P., Harvey-White, J., Luft, F.C., Sharma, A.M., Jordan, J., Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54 (2005), 2838–2843.
43. [43] Abdulnour, J., Yasari, S., Rabasa-Lhoret, R., Faraj, M., Petrosino, S., Piscitelli, F., Prud'homme, D., Di Marzo, V., Circulating endocannabinoids in insulin sensitive vs. insulin resistant obese postmenopausal women. A MONET Group Study, Obesity (Silver Spring), 2013.
44. [44] Chanderbhan, R., Hodges, V.A., Treadwell, C.R., Vahouny, G.V., Prostaglandin synthesis in rat adrenocortical cells. J. Lipid Res 20 (1979), 116–124.
45. [45] Marcus, A.J., Ullman, H.L., Safier, L.B., Lipid composition of subcellular particles of human blood platelets. J. Lipid Res 10 (1969), 108–114.
46. [46] Weiner, T.W., Sprecher, H., 22-Carbon polyenoic acids. Incorporation into platelet phospholipids and the synthesis of these acids from 20-carbon polyenoic acid precursors by intact platelets. J. Biol. Chem 260 (1985), 6032–6038.
47. [47] Aukema, H.M., Holub, B.J., Effect of dietary supplementation with a fish oil concentrate on the alkenylacyl class of ethanolamine phospholipid in human platelets. J. Lipid Res 30 (1989), 59–64.
48. [48] Comai, K., Farber, S.J., Paulsrud, J.R., Analyses of renal medullary lipid droplets from normal, hydronephrotic, and indomethacin treated rabbits. Lipids 10 (1975), 555–561.
49. [49] Moncada, S., Gryglewski, R., Bunting, S., Vane, J.R., An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263 (1976), 663–665.
50. [50] Croset, M., Lagarde, M., In vitro incorporation and metabolism of icosapentaenoic and docosahexaenoic acids in human platelets—•effect on aggregation. Thromb. Haemost 56 (1986), 57–62.
51. [51] Hatmi, M., Lussiana, J.P., Junien, J.L., Burke, J., Vargaftig, B.B., Interference of eicosapentaenoic and docosahexaenoic acids with arachidonate-and U46619-induced platelet activation and desensitization. Biochem. Pharmacol 37 (1988), 481–489.
52. [52] VanRollins, M., Horrocks, L., Sprecher, H., Metabolism of 7,10,13,16-docosatetraenoic acid to dihomo-thromboxane, 14-hydroxy-7,10,12-nonadecatrienoic acid and hydroxy fatty acids by human platelets. Biochim. Biophys. Acta 833 (1985), 272–280.
53. [53] Walsh, P., Behrens, N., Carvallo Chaigneau, F.R., McEligot, H., Agrawal, K., Newman, J.W., Anderson, M., Gershwin, L.J., A randomized placebo controlled trial of ibuprofen for respiratory syncytial virus infection in a bovine model. PLoS One, 11, 2016, e0152913.
54. [54] Ulu, A., Harris, T.R., Morisseau, C., Miyabe, C., Inoue, H., Schuster, G., Dong, H., Iosif, A.M., Liu, J.Y., Weiss, R.H., Chiamvimonvat, N., Imig, J.D., Hammock, B.D., Anti-inflammatory effects of omega-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. J. Cardiovasc. Pharmacol 62 (2013), 285–297.
55. [55] Wagner, K., Inceoglu, B., Hammock, B.D., Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception. Prostaglandins Other Lipid Mediat 96 (2011), 76–83.
56. [56] Zhang, G., Panigrahy, D., Mahakian, L.M., Yang, J., Liu, J.Y., Stephen Lee, K.S., Wettersten, H.I., Ulu, A., Hu, X., Tam, S., Hwang, S.H., Ingham, E.S., Kieran, M.W., Weiss, R.H., Ferrara, K.W., Hammock, B.D., Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 6530–6535.
57. [57] Hutchins-Wiese, H.L., Kleppinger, A., Annis, K., Liva, E., Lammi-Keefe, C.J., Durham, H.A., Kenny, A.M., The impact of supplemental n − 3 long chain polyunsaturated fatty acids and dietary antioxidants on physical performance in postmenopausal women. J. Nutr. Health Aging 17 (2013), 76–80.